Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | ACE | P12821 | 9/20 | 0.53 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.53 |
| ▸ | REN | P00797 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PEPD | P12955 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2636385 | 1.00 | LMNA (0.68) | LMNAHSD17B10CYP2C19ACERIPK1 | |
| SCHEMBL11993551 | 1.00 | LMNA (0.68) | LMNAHSD17B10CYP2C19ACERIPK1 | |
| SCHEMBL24339739 | 0.94 | LMNA (0.61) | LMNAHSD17B10CYP2C19ACERIPK1 | |
| SCHEMBL19075664 | 0.94 | LMNA (0.61) | LMNAHSD17B10CYP2C19ACERIPK1 | |
| SCHEMBL11922857 | 0.94 | LMNA (0.61) | LMNAHSD17B10CYP2C19ACERIPK1 | |
| SCHEMBL19075666 | 0.88 | LMNA (0.53) | LMNAHSD17B10CYP2C19ACERIPK1 | |
| SCHEMBL9392063 | 0.85 | LMNA (0.69) | LMNAHSD17B10CYP2C19ACEREN | |
| SCHEMBL9162445 | 0.85 | LMNA (0.64) | LMNAHSD17B10CYP2C19ACEREN | |
| SCHEMBL9162833 | 0.85 | LMNA (0.64) | LMNAHSD17B10CYP2C19ACEREN | |
| SCHEMBL7321336 | 0.85 | LMNA (0.69) | LMNAHSD17B10CYP2C19ACEREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5250517-A | Hypotensive and cardiotonic agents; cardiac insufficiency | HOFFMANN-LA ROCHE INC. (US) | 1993-10-05 | — | — | US | claimed |
| CN-111848321-B | Chiral aminated sulfoxide and preparation method thereof | 南方科技大学 | 2023-01-03 | — | — | CN | disclosed |
| US-20220098214-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING FIBROSIS | YALE UNIVERSITY | 2022-03-31 | — | — | US | disclosed |
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-9527846-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-12-27 | — | — | US | disclosed |
| EP-2788349-B1 | KINASE INHIBITORS | CHIESI FARMA SPA (IT) | 2016-10-26 | — | — | EP | disclosed |
| US-20160229852-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-08-11 | — | — | US | disclosed |
| US-8907094-B2 | Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-12-09 | — | — | US | disclosed |
| US-20140323470-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-10-30 | — | — | US | disclosed |
| EP-2788349-A1 | KINASE INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2014-10-15 | — | — | EP | disclosed |
| US-8703761-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-04-22 | — | — | US | disclosed |
| WO-2013083604-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-06-13 | — | — | WO | disclosed |
| US-20130150343-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-06-13 | — | — | US | disclosed |
| EP-2559455-A1 | Heteroaryl derivatives as DGAT1 inhibitors | Novartis AG (CH) | 2013-02-20 | — | — | EP | disclosed |
| EP-2548618-A2 | Organic compounds | Novartis AG (CH) | 2013-01-23 | — | — | EP | disclosed |
| US-20100022513-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-01-28 | — | — | US | disclosed |
| WO-2010007046-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | LMNA 462/4885HSD17B10 2827/4885CYP2C19 565/4885 |
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | RDX, C1R, MTX1 | LMNA 462/4885HSD17B10 2827/4885CYP2C19 565/4885 |
| US-20100022513-A1 | ORGANIC COMPOUNDS | DGAT1, DGAT2, SOAT1 | LMNA 4089/4885HSD17B10 32/4885CYP2C19 692/4885 |
| US-20160229852-A1 | KINASE INHIBITORS | MAPK1, MAP3K1, MAPK6 | LMNA 2358/4885HSD17B10 3402/4885CYP2C19 1267/4885 |
| US-20140323470-A1 | KINASE INHIBITORS | MAPK1, MAP3K1, MAPK6 | LMNA 2358/4885HSD17B10 3402/4885CYP2C19 1267/4885 |
| US-20220098214-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING FIBROSIS | DUSP5, DUSP4, DUSP6 | LMNA 2987/4885HSD17B10 1520/4885CYP2C19 4862/4885 |
| US-20130150343-A1 | KINASE INHIBITORS | MAPK1, MAP3K1, MAPK6 | LMNA 2358/4885HSD17B10 3402/4885CYP2C19 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.